Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-diabetic drugs of the thiazolidinedione (TZD) structural class as well as α-lipoic acid activate peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor that controls glucose metabolism and lipid homeostasis. CAY10506 is a hybrid lipoic acid-TZD derivative that transactivates human PPARγ with an EC50 value of 10 μM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | $853 | 35 days |
Description | Anti-diabetic drugs of the thiazolidinedione (TZD) structural class as well as α-lipoic acid activate peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor that controls glucose metabolism and lipid homeostasis. CAY10506 is a hybrid lipoic acid-TZD derivative that transactivates human PPARγ with an EC50 value of 10 μM. |
Alias | CAY10506 |
Molecular Weight | 454.63 |
Formula | C20H26N2O4S3 |
Cas No. | 292615-75-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol: 3 mg/mL DMF: 5 mg/mL DMSO:PBS(pH 7.2) (1:5): 0.15 mg/mL DMSO: 5 mg/mL |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.